1. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors;Strosberg;N. Engl. J. Med.,2017
2. European Commission. EU Guidelines to Good Manufacturing Practice – Medicinal Products for Human and Veterinary Use. Annex 3. Manufacture of Radiopharmaceuticals. Brussels, September 01 2008. http://academy.gmp-compliance.org/guidemgr/files/2008_09_ANNEX3%5b1%5d.PDF (accessed 31 October 2019).
3. Lutathera, European Medicines Agency. Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf (accessed 11 December 2019).
4. European Medicines Agency, Committee for Human Medicinal Products (CHMP), Guideline on Radiopharmaeceuticals, London, November 26, 2008. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-radiopharmaceuticals-revision-1_en.pdf (accessed 31 October 2019).
5. European Directorate for the Quality of Medicines & Healthcare (EDQM). Guide for the elaboration of monographs on radiopharmaceutical preparations. Edition 2018. https://www.edqm.eu/sites/default/files/guide_-_guide_for_the_elaboration_of_monographs_on_radio-pharmaceutical_preparations_-_october_2018.pdf (accessed 12 June 2019).